{"id":568978,"date":"2021-10-14T13:10:02","date_gmt":"2021-10-14T13:10:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=568978"},"modified":"2021-10-14T13:10:02","modified_gmt":"2021-10-14T13:10:02","slug":"cervical-cancer-market-industry-analysis-epidemiology-treatment-therapies-and-key-companies-including-regeneron-pharmaceuticals-zeria-pharmaceutical-advaxis-astrazeneca-others-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cervical-cancer-market-industry-analysis-epidemiology-treatment-therapies-and-key-companies-including-regeneron-pharmaceuticals-zeria-pharmaceutical-advaxis-astrazeneca-others-delveinsight_568978.html","title":{"rendered":"Cervical Cancer Market: Industry Analysis, Epidemiology, Treatment, Therapies and Key Companies including Regeneron Pharmaceuticals, Zeria Pharmaceutical, Advaxis, AstraZeneca &#038; Others | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1627018024.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cervical Cancer Market: Industry Analysis, Epidemiology, Treatment, Therapies and Key Companies including Regeneron Pharmaceuticals, Zeria Pharmaceutical, Advaxis, AstraZeneca &amp; Others | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1627018024.jpeg\" alt=\"Cervical Cancer Market: Industry Analysis, Epidemiology, Treatment, Therapies and Key Companies including Regeneron Pharmaceuticals, Zeria Pharmaceutical, Advaxis, AstraZeneca &amp; Others | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Cervical Cancer Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Cervical Cancer<\/a><\/strong> occurs in the cells of the cervix and usually originates in the transformation zone of the cervix, and spreads to regional lymph nodes with parametrial invasion also common.<\/p>\n<p style=\"text-align: justify;\">Most cases of cervical cancer are caused by infection with human papillomavirus (HPV). Apart from HPV, other factors that can also increase the risk include: human immunodeficiency virus (HIV), chlamydia, smoking, obesity, family history of cervical cancer, diet low in fruits and vegetables, taking birth control pills, and having three full-term pregnancies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong>Cervical Cancer Market Insights, Epidemiology, and Market Forecast-2030<\/strong>&#8221; report delivers an in-depth understanding of the Cervical Cancer, historical and forecasted epidemiology as well as the Cervical Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some facts of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Cervical Cancer Market<\/a> Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The incidence of cervical cancer in 7MM (US, UK, Germany, Italy, Spain, France &amp; Japan) in 2020 is expected to be <strong>43,712<\/strong>.<\/li>\n<li>In the 7MM, the <strong>United States<\/strong> is the major contributor to the cervical cancer market revenue in 2020, and the region is expected to hold its position in the upcoming years.<\/li>\n<li>Key companies propelling the market size include <strong>Regeneron, AstraZeneca, Lovance, Zeria Pharmaceutical, Seattle Genetics\/Genmab, Agenus Bio, Roche, Akeso Biopharma and Vaccibody\/Roche<\/strong>, and among others.<\/li>\n<li>Launch of cervical cancer pipeline therapies, including <strong>Cemiplimab (Regeneron), Durvalumab (AstraZeneca), LN-145 (Iovance), Z-100 (Zeria Pharmaceutical), Tisotumab vedotin (Seattle Genetics\/Genmab)<\/strong> in the next decade is expected to propel the market growth.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cervical-cancer-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/cervical-cancer-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>&ldquo;As per WHO estimates, Cervical Cancer is the fourth most common cancer in women.&rdquo;<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Clinical presentation depends mainly on the location and extent of disease. Precancerous changes or very early stage disease are usually asymptomatic and are detected on a cervical smear. Symptoms usually appear when the tumour causes spontaneous or contact bleeding, or pain if lymph nodes are involved.<\/p>\n<p style=\"text-align: justify;\">All women are at risk for cervical cancer. It occurs most often in women over age 30. There&rsquo;s more than one kind of cervical cancer.<\/p>\n<ul style=\"text-align: justify;\">\n<li>Squamous cell carcinoma-This forms in the lining of cervix. It&rsquo;s found in up to 90% of cases.<\/li>\n<li>Adenocarcinoma-This forms in the cells that produce mucus.<\/li>\n<li>Mixed carcinoma-This has features of the two other types.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">DelveInsight estimated that cervical cancer is most often diagnosed in women between the ages of 35 and 44, with the average age at diagnosis being 50. The late diagnosis in women is a consequence of a lack of vaccination and screening in women in the early stages of their lives.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cervical-cancer-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/cervical-cancer-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Cervical Cancer Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Regeneron Pharmaceuticals<\/li>\n<li>Zeria Pharmaceutical<\/li>\n<li>Advaxis<\/li>\n<li>AstraZeneca<\/li>\n<li>Immunitor<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Cervical cancer Therapies<\/a> Covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Libtayo<\/li>\n<li>Z-100<\/li>\n<li>ADXS11&ndash;001<\/li>\n<li>IMFINZ<\/li>\n<li>V3-Cervix<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: https:\/\/www.delveinsight.com\/sample-request\/cervical-cancer-market<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Cervical Cancer<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Cervical Cancer<\/p>\n<p style=\"text-align: justify;\">4. Cervical Cancer: Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Cervical Cancer: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Cervical Cancer Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Cervical Cancer Treatment<\/p>\n<p style=\"text-align: justify;\">11. Marketed Products<\/p>\n<p style=\"text-align: justify;\">12. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13. Cervical Cancer: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Cervical Cancer<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cervical-cancer-market-industry-analysis-epidemiology-treatment-therapies-and-key-companies-including-regeneron-pharmaceuticals-zeria-pharmaceutical-advaxis-astrazeneca-others-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cervical-cancer-market-industry-analysis-epidemiology-treatment-therapies-and-key-companies-including-regeneron-pharmaceuticals-zeria-pharmaceutical-advaxis-astrazeneca-others-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cervical Cancer Market Cervical Cancer occurs in the cells of the cervix and usually originates in the transformation zone of the cervix, and spreads to regional lymph nodes with parametrial invasion also common. Most cases of cervical cancer are caused &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cervical-cancer-market-industry-analysis-epidemiology-treatment-therapies-and-key-companies-including-regeneron-pharmaceuticals-zeria-pharmaceutical-advaxis-astrazeneca-others-delveinsight_568978.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-568978","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/568978","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=568978"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/568978\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=568978"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=568978"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=568978"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}